Vir Biotechnology (VIR) Operating Leases (2020 - 2026)
Vir Biotechnology (VIR) posted Operating Leases of $86.6 million for Q1 2026, down 2.72% sequentially from $89.1 million in Q4 2025, and down 1.74% YoY from $88.2 million in Q1 2025.
Vir Biotechnology (VIR) Operating Leases (2020 - 2026) Analysis & Trends
Vir Biotechnology has reported Operating Leases for 7 years, with the latest figure at $86.6 million in Q1 2026.
- Quarterly Operating Leases fell 1.74% year-over-year to $86.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.6 million (down 1.74% YoY) and the FY2025 annual result came in at $89.1 million, down 9.03% from the prior year.
- Operating Leases retreated to $86.6 million in Q1 2026 per VIR's latest filing, from $89.1 million in the prior quarter.
- Over five years, Operating Leases peaked at $132.8 million in Q1 2022 and troughed at $86.6 million in Q1 2026.
- A 5-year average of $107.2 million and a median of $109.2 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2024: Operating Leases jumped 99.37% in 2022, then dropped 19.35% in 2024.
- Over 5 years, Operating Leases stood at $123.8 million in 2022, then fell by 9.82% to $111.7 million in 2023, then fell by 12.34% to $97.9 million in 2024, then fell by 9.03% to $89.1 million in 2025, then dropped by 2.72% to $86.6 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $86.6 million, $89.1 million, and $91.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 84.14 Mn |
| Mar 31, 2026 | 86.64 Mn |
| Dec 31, 2025 | 89.05 Mn |
| Sep 30, 2025 | 91.22 Mn |
| Jun 30, 2025 | 93.41 Mn |
| Mar 31, 2025 | 88.17 Mn |
| Dec 31, 2024 | 97.89 Mn |
| Sep 30, 2024 | 93.41 Mn |
| Jun 30, 2024 | 95.02 Mn |
| Mar 31, 2024 | 109.17 Mn |
| Dec 31, 2023 | 111.67 Mn |
| Sep 30, 2023 | 114.12 Mn |
| Jun 30, 2023 | 117.82 Mn |
| Mar 31, 2023 | 121.46 Mn |
| Dec 31, 2022 | 123.84 Mn |
| Sep 30, 2022 | 126.94 Mn |
| Jun 30, 2022 | 130.21 Mn |
| Mar 31, 2022 | 132.81 Mn |
| Dec 31, 2021 | 133.56 Mn |
| Sep 30, 2021 | 68.60 Mn |